Tag Archives: BIIB

Top 10 Biotech Stocks To Own For 2019

The unicorn class just breathed a sigh of relief. Dropbox (Pending:DBX), once the poster child for excessive private valuations, priced above its range at $21 and then popped 36%. The most highly-valued tech IPO since Snap (NYSE:SNAP), Dropbox boasts over $1 billion in annual sales, paired with fast growth and expanding margins. The takeaway: Expect more tech.

Broader markets dropped. This past week, the IPO Index traded off -3.6% and the S&P 500 fell -6.0%. The VIX Volatility Index surged to about 25, the point at which IPOs start postponing.

Two IPOs did postpone this week: Israeli biotech PolyPid (Pending:POLY) and blank check company Terrapin 4. And even with new tariffs roiling Chinese stocks, two deals from China were completed: Sunlands Online Education (STG; -3%) and micro-cap fintech Golden Bull (DNJR; +16%).

3 IPOs During the Week of March 19th, 2018

Issuer
Business

Top 10 Biotech Stocks To Own For 2019: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Russell Investments Group Ltd. boosted its holdings in Biogen (NASDAQ:BIIB) by 40.1% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 183,809 shares of the biotechnology company’s stock after buying an additional 52,654 shares during the period. Russell Investments Group Ltd.’s holdings in Biogen were worth $50,222,000 as of its most recent SEC filing.

  • [By Dan Caplinger]

    The iShares biotech ETF has a structure that’s familiar to anyone who invests regularly in exchange-traded funds. The ETF tracks an index of nearly 200 biotech and pharmaceutical stocks, with roughly 80% of assets dedicated to true biotechs and the rest split evenly between pharma and life sciences equipment and services providers. Top ETF holdings Biogen (NASDAQ:BIIB), Amgen (NASDAQ:AMGN), and Gilead Sciences (NASDAQ:GILD) make up a total of roughly 25% of the fund’s assets.

  • [By Brian Orelli]

    Data source: Alkermes.

    What happened with Alkermes this quarter?
    Sales of opioid and alcohol-dependence drug Vivitrol increased 11% year over year as states including Michigan, Pennsylvania, California, Florida, and Kentucky increase coverage of the drug as a treatment option for patients suffering from substance-use disorder. Schizophrenia drug Aristada saw sales increase 72% year over year and 35% quarter over quarter, thanks to the launch of Aristada Initio, which helps patients get started on the drug while hospitalized. Alkermes estimates it captured 29% of new prescriptions for long-acting aripiprazole, the active ingredient in Aristada. Ampyra, which goes by Fampyra outside the U.S., brought in $38.8 million, basically flat year over year, which wasn’t bad since a generic launched in the U.S. last year. Manufacturing and royalty revenues for Risperdal Consta, Invega Sustenna, and Invega Trinza were up about 4% year over year. Fourth-quarter revenue also included a one-time payment of $26.7 million, which came from the sale of certain royalty streams by Zealand Pharma to Royalty Pharma. In November, Alkermes reported positive data from a second phase-3 clinical trial for schizophrenia drug ALKS 3831 that showed patients taking the drug had lower weight gain than those taking olanzapine. In December, Alkermes and its partner Biogen (NASDAQ:BIIB) filed for Food and Drug Administration (FDA) approval of diroximel fumarate, which Biogen plans to market under the name Vumerity. In January, Alkermes got bad news from the FDA when the agency turned down the marketing application for its depression drug ALKS 5461.

    Image source: Getty Images.

  • [By Joseph Griffin]

    Here are some of the news stories that may have effected Accern’s analysis:

    Get Biogen alerts:

    Biogen (BIIB) Expected to Post Quarterly Sales of $3.24 Billion (americanbankingnews.com) Biogen Inc (NASDAQ:BIIB): Does The Earnings Decline Make It An Underperformer? (finance.yahoo.com) 5 Trade Ideas For Monday: AMTD, BIIB, DEO, FITB, TECK (investing.com) $5.29 EPS Expected for Biogen (BIIB) This Quarter (americanbankingnews.com) Biogen (BIIB) Upgraded by ValuEngine to “Hold” (americanbankingnews.com)

    Shares of Biogen traded up $5.45, reaching $281.51, during midday trading on Wednesday, according to MarketBeat Ratings. 1,514,169 shares of the company’s stock were exchanged, compared to its average volume of 1,729,786. Biogen has a 52-week low of $276.94 and a 52-week high of $281.57. The firm has a market cap of $59.58 billion, a price-to-earnings ratio of 12.91, a PEG ratio of 1.65 and a beta of 0.84. The company has a debt-to-equity ratio of 0.42, a quick ratio of 2.95 and a current ratio of 3.23.

  • [By Logan Wallace]

    Biogen Inc (NASDAQ:BIIB) EVP Michael D. Ehlers sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, September 26th. The stock was sold at an average price of $350.00, for a total value of $350,000.00. Following the completion of the transaction, the executive vice president now owns 4,281 shares of the company’s stock, valued at $1,498,350. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Top 10 Biotech Stocks To Own For 2019: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Joseph Griffin]

    ValuEngine upgraded shares of ArQule (NASDAQ:ARQL) from a buy rating to a strong-buy rating in a research report released on Tuesday.

    Several other equities analysts have also issued reports on ARQL. Zacks Investment Research upgraded ArQule from a hold rating to a buy rating and set a $2.50 price objective for the company in a research report on Tuesday, March 20th. BidaskClub upgraded ArQule from a buy rating to a strong-buy rating in a research report on Saturday, March 24th. B. Riley set a $4.00 price objective on ArQule and gave the company a buy rating in a research report on Monday, March 26th. Leerink Swann upgraded ArQule from a market perform rating to an outperform rating in a research report on Thursday, April 5th. Finally, Roth Capital boosted their price objective on ArQule from $5.00 to $6.00 and gave the company a buy rating in a research report on Tuesday, April 17th. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and two have issued a strong buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $5.35.

  • [By Lisa Levin] Gainers
    Foot Locker, Inc. (NYSE: FL) rose 15.3 percent to $53.50 in pre-market trading after the company reported better-than-expected results for its first quarter.
    Evofem Biosciences, Inc. (NASDAQ: EVFM) rose 10.4 percent to $4.58 in pre-market trading. Evofem Biosciences reported closing of public offering of common stock and warrants.
    Resonant Inc. (NASDAQ: RESN) rose 7.3 percent to $4.88 in pre-market trading after declining 1.94 percent on Thursday.
    SolarEdge Technologies, Inc. (NASDAQ: SEDG) shares rose 5.7 percent to $59.65 in pre-market trading after falling 8.43 percent on Thursday.
    Yirendai Ltd. (NYSE: YRD) rose 5 percent to $30.00 in pre-market trading after reporting Q1 results.
    Deckers Outdoor Corp (NYSE: DECK) rose 4.9 percent to $108.75 in pre-market trading after reporteingd better-than-expected results for its fiscal fourth quarter.
    Blue Apron Holdings, Inc. (NYSE: APRN) rose 4.2 percent to $3.21 in pre-market trading after gaining 3.70 percent on Thursday.
    Recro Pharma, Inc. (NASDAQ: REPH) rose 4 percent to $5.85 in pre-market trading after dropping 54.67 percent on Thursday.
    ArQule, Inc. (NASDAQ: ARQL) rose 3.8 percent to $4.70 in pre-market trading after gaining 4.86 percent on Thursday.
    Babcock & Wilcox Enterprises, Inc. (NYSE: BW) shares rose 2.9 percent to $2.85 in pre-market trading after climbing 7.78 percent on Thursday.
    Bilibili Inc. (NASDAQ: BILI) shares rose 2.5 percent to $14.20 in pre-market trading after surging 11.33 percent on Thursday.

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on ArQule (ARQL)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    BidaskClub upgraded shares of ArQule (NASDAQ:ARQL) from a hold rating to a buy rating in a report released on Saturday.

    A number of other research firms have also issued reports on ARQL. Roth Capital upped their price target on ArQule from $5.00 to $6.00 and gave the company a buy rating in a research report on Tuesday, April 17th. Leerink Swann upgraded ArQule from a market perform rating to an outperform rating in a research report on Thursday, April 5th. Zacks Investment Research lowered ArQule from a buy rating to a hold rating in a research report on Wednesday, April 4th. ValuEngine upgraded ArQule from a hold rating to a buy rating in a research report on Wednesday, May 2nd. Finally, B. Riley set a $4.00 price target on ArQule and gave the company a buy rating in a research report on Monday, March 26th. Seven analysts have rated the stock with a buy rating, The stock currently has an average rating of Buy and an average target price of $4.69.

  • [By Lisa Levin] Gainers
    Melinta Therapeutics, Inc. (NASDAQ: MLNT) shares surged 20.6 percent to $6.39. WBB Securities upgraded Melinta Therapeutics from Hold to Speculative Buy.
    Shoe Carnival, Inc. (NASDAQ: SCVL) shares climbed 17.2 percent to $30.87 after the company reported upbeat quarterly earnings.
    Acorn International, Inc. (NYSE: ATV) shares rose 15.2 percent to $28.804 after the company declared a special one-time cash dividend of $14.97 per ADS.
    Foot Locker, Inc. (NYSE: FL) gained 15 percent to $53.35 after the company reported better-than-expected results for its first quarter.
    Sears Hometown and Outlet Stores, Inc. (NASDAQ: SHOS) surged 14.2 percent to $2.625.
    ArQule, Inc. (NASDAQ: ARQL) rose 13 percent to $5.12 after gaining 4.86 percent on Thursday.
    Quality Systems, Inc. (NASDAQ: QSII) gained 12.8 percent to $16.97 after the company posted better-than-expected FQ4 results.
    Loma Negra Compañía Industrial Argentina Sociedad Anónima (NYSE: LOMA) shares rose 12 percent to $12.94.
    ArQule, Inc. (NASDAQ: ARQL) shares rose 12 percent to $5.07.
    Mirati Therapeutics, Inc. (NASDAQ: MRTX) climbed 11.4 percent to $43.50.
    Zai Lab Limited (NASDAQ: ZLAB) gained 11.3 percent to $24.7000.
    Zymeworks Inc. (NASDAQ: ZYME) rose 9.7 percent to $19.64.
    Park City Group, Inc. (NASDAQ: PCYG) climbed 9 percent to $7.90.
    Roku, Inc. (NASDAQ: ROKU) gained 7.9 percent to $38.82 after Citron reversed previously bearish position on the stock.
    Sears Holdings Corporation (NASDAQ: SHLD) shares jumped 7.3 percent to $3.55.
    Deckers Outdoor Corp (NYSE: DECK) rose 3.5 percent to $107.27 after reporting better-than-expected results for its fiscal fourth quarter.

    Check out these big penny stock gainers and losers

Top 10 Biotech Stocks To Own For 2019: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Motley Fool Staff]

    Alnylam’s (NASDAQ:ALNY) Onpattro is the first Food and Drug Administration (FDA)-approved RNAi therapy. However, competition is fast approaching and could make it difficult for Alnylam to pocket profits. Can Onpattro carve out significant sales as a treatment for polyneuropathy in hereditary transthyretin-mediated (hATTR) amyloidosis?

  • [By Brian Orelli]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) and Ionis Pharmaceuticals (NASDAQ:IONS) looked to be in a two-horse race to develop TTR amyloidosis (ATTR) drugs. Alnylam recently got its drug Onpattro approved, while Ionis Pharmaceuticals and its marketing partner Akcea Therapeutics (NASDAQ:AKCA) should hear about Tegsedi by Oct. 6. Tegsedi was approved in the EU last month.

  • [By Brian Orelli]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) updated investors last month on how the launch of Onpattro, its first drug that was approved to treat transthyretin-mediated amyloidosis (ATTR), was going at the J.P. Morgan Healthcare Conference.

  • [By Jim Crumly]

    As for individual stocks, shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) fell despite the announcement of its first-ever drug approval, and those of Sysco (NYSE:SYY) rose on earnings.

  • [By Sean Williams, Chuck Saletta, and Brian Feroldi]

    So, which biotech stocks should you consider buying in June? That’s a question we posed to three of our healthcare-focused investors. Interestingly enough, mid-cap biotech stocks are the clear flavor of the month. If biotech is on your radar in June, our investors suggest you consider Ionis Pharmaceuticals (NASDAQ:IONS), Spark Therapeutics (NASDAQ:ONCE), and Alnylam Pharmaceuticals (NASDAQ:ALNY).

  • [By Brian Orelli]

    Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) were up 19% at 12:04 p.m. EDT on Monday after rival Pfizer (NYSE:PFE) released data for its transthyretin amyloid (ATTR) drug tafamidis at the ESC Congress 2018, which were also published in the New England Journal of Medicine. Earlier this month, Alnylam got its ATTR drug, Onpattro, approved by the Food and Drug Administration. Shares of Ionis Pharmaceuticals (NASDAQ:IONS) and Akcea Therapeutics (NASDAQ:AKCA), which are jointly developing another ATTR drug, Tegsedi, are up 10% and 2.6% respectively.

Top 10 Biotech Stocks To Own For 2019: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Todd Campbell]

    Amgen (NASDAQ:AMGN) may not be as exciting a stock to own as clinical-stage upstarts, but shares in this biotech Goliath have been mounting a rally lately that should make every investor take notice. So far in 2018, Amgen’s rewarded investors with an 18% return.

  • [By Keith Speights]

    Amgen (NASDAQ:AMGN) has been the hands-down winner over Celgene (NASDAQ:CELG) in terms of stock performance over the last year. It’s the same story for revenue generated. Celgene beat Amgen in earnings, but only because of a technicality: Amgen incurred a big one-time tax hit in 2017.

  • [By Logan Wallace]

    AlphaMark Advisors LLC cut its position in shares of Amgen (NASDAQ:AMGN) by 5.5% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 27,973 shares of the medical research company’s stock after selling 1,638 shares during the period. Amgen comprises about 2.0% of AlphaMark Advisors LLC’s investment portfolio, making the stock its 7th largest position. AlphaMark Advisors LLC’s holdings in Amgen were worth $4,769,000 at the end of the most recent reporting period.

  • [By Joseph Griffin]

    Field & Main Bank grew its stake in shares of Amgen (NASDAQ:AMGN) by 9.1% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,153 shares of the medical research company’s stock after buying an additional 345 shares during the quarter. Field & Main Bank’s holdings in Amgen were worth $708,000 at the end of the most recent quarter.

  • [By Stephan Byrd]

    Marco Investment Management LLC raised its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 4.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 118,601 shares of the medical research company’s stock after buying an additional 5,265 shares during the period. Amgen comprises approximately 3.4% of Marco Investment Management LLC’s portfolio, making the stock its 3rd largest position. Marco Investment Management LLC’s holdings in Amgen were worth $21,893,000 as of its most recent SEC filing.

Top Biotech Stocks To Own Right Now

The Manufacturers Life Insurance Company increased its holdings in BIO-TECHNE Corp (NASDAQ:TECH) by 1.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 89,922 shares of the biotechnology company’s stock after acquiring an additional 1,318 shares during the period. The Manufacturers Life Insurance Company owned about 0.24% of BIO-TECHNE worth $13,582,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Financial Gravity Companies Inc. purchased a new stake in BIO-TECHNE in the 4th quarter worth about $118,000. Advisory Services Network LLC lifted its stake in BIO-TECHNE by 1,423.3% in the 4th quarter. Advisory Services Network LLC now owns 1,112 shares of the biotechnology company’s stock worth $144,000 after acquiring an additional 1,039 shares in the last quarter. Institutional & Family Asset Management LLC purchased a new stake in BIO-TECHNE in the 1st quarter worth about $162,000. Advisor Group Inc. lifted its stake in BIO-TECHNE by 64.5% in the 4th quarter. Advisor Group Inc. now owns 1,288 shares of the biotechnology company’s stock worth $167,000 after acquiring an additional 505 shares in the last quarter. Finally, Stonebridge Capital Advisors LLC purchased a new stake in shares of BIO-TECHNE during the 1st quarter worth about $203,000. 94.48% of the stock is owned by hedge funds and other institutional investors.

Top Biotech Stocks To Own Right Now: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By Cory Renauer]

    Biotech traders get heaps of attention, but buying promising young drugmakers and holding them for the long term is a far easier way to get rich. Case in point: Spreading $10,000 evenly among shares of Biogen Inc. (NASDAQ:BIIB), Celgene Corporation (NASDAQ:CELG), and Gilead Sciences Inc. (NASDAQ:GILD) around this time in 1998 would have made you a millionaire already. 

  • [By George Budwell]

    Not surprisingly, biotech titans Celgene (NASDAQ:CELG) and Biogen (NASDAQ:BIIB) are among the leaders in this ongoing biopharma revolution. So, with that theme in mind, let’s attempt to gauge which of these top biotechs is the more attractive long-term buy for investors right now.

  • [By Brian Orelli]

    Likewise, Biogen (NASDAQ:BIIB) and Ionis Pharmaceuticals (NASDAQ:IONS), which have the only SMA drug on the market, are feeling the heat from the promising data with shares down 5.6% and 7.3%, respectively.

  • [By Chris Lange]

    Short interest in Biogen Inc. (NASDAQ: BIIB) increased to 4.00 million shares from the previous 3.91 million. The stock recently traded at $346.90, within a 52-week range of $249.17 to $388.67.

Top Biotech Stocks To Own Right Now: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Todd Campbell]

    One of these two drugs is Amgen’s (NASDAQ:AMGN) Repatha, and the other is Praluent, which was co-developed by Sanofi SA (NYSE:SNY) and Regeneron Pharmaceuticals (NASDAQ:REGN). Both drugs launched to billion-dollar blockbuster expectations, but because they’re complex biologics that are expensive to make, they cost about $14,000 per year. Their high cost, plus the fact that they’re injected rather than taken orally, may make them best suited for patients with stubbornly high cholesterol who are at the greatest risk of heart disease.

  • [By Chris Lange]

    Amgen Inc. (NASDAQ: AMGN) is waiting for the FDA to review its Biologics License Application (BLA) for Aimovig (erenumab) for the prevention of migraine in patients experiencing four or more migraine days per month. The FDA has set a PDUFA date for May 17.

  • [By Brian Feroldi]

    The study in question is called ADVANCE. This phase 3 trial was designed to demonstrate noninferiority of Spectrum’s drug Rolontis when compared to Amgen’s (NASDAQ:AMGN) megablockbuster drug Neulasta in patients with early-stage breast cancer.

Top Biotech Stocks To Own Right Now: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Money Morning Staff Reports]

    But Blink and our other penny stocks to watch are unlikely to continue to lock in such spectacular gains in June. After looking at our 10 top penny stocks to watch this month, we’ll show you a small-cap stock with great profit potential in its future…

    Penny Stock Current Share Price Law Month’s Gain
     Blink Charging Co. (Nasdaq: BLNK) $7.07 439.85%
    Senes Tech Inc. (Nasdaq: SNES) $1.27 175.40%
    Vivis Inc. (Nasdaq: VVUS) $0.77 150.41%
    Adomani Inc. (Nasdaq: ADOM) $1.49 137.68%
    NF Energy Saving Co. (Nasdaq: NFEC) $2.34 134.88%
    Vaalco Energy Inc. (NYSE: EGY) $2.15 109.06%
    Heat Biologics Inc. (Nasdaq: HTBX) $2.35 99.12%
    ArQule Inc. (Nasdaq: ARQL) $4.88 90.74%
    LiqTech International Inc. (NYSE: LIQT) $0.66 85.60%
    Transenterix Inc. (NYSE: TRXC) $3.46 77.84%

    While last month’s gains are tremendous, they also illustrate the inherent dangers that come with investing in penny stocks.

  • [By Joseph Griffin]

    Shares of ArQule, Inc. (NASDAQ:ARQL) were down 5.4% during trading on Wednesday . The company traded as low as $4.71 and last traded at $4.73. Approximately 3,358,864 shares traded hands during trading, an increase of 289% from the average daily volume of 863,008 shares. The stock had previously closed at $5.00.

  • [By Maxx Chatsko]

    Shares of development-stage biopharma ArQule (NASDAQ:ARQL) rose nearly 17% today after the company announced two appointments to its management team in two newly created positions. Dr. Marc Schegerin will serve as senior vice president, corporate strategy, communication, and finance. Dr. Shirish Hirani will serve as senior vice president, program management and product planning. 

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on ArQule (ARQL)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top Biotech Stocks To Own Right Now: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Joseph Griffin]

    BidaskClub lowered shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a strong-buy rating to a buy rating in a research report released on Monday.

  • [By Shane Hupp]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lowered by equities research analysts at Morgan Stanley from $107.00 to $99.00 in a report released on Friday. The firm presently has an “equal weight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s price objective would indicate a potential upside of 3.97% from the stock’s current price.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Best Biotech Stocks To Watch Right Now

ADMA Biologics Inc (NASDAQ:ADMA) – Equities researchers at Oppenheimer issued their Q1 2019 earnings per share estimates for ADMA Biologics in a research note issued on Monday, August 13th. Oppenheimer analyst L. Gershell forecasts that the biotechnology company will post earnings per share of ($0.26) for the quarter. Oppenheimer currently has a “Buy” rating and a $13.00 price target on the stock. Oppenheimer also issued estimates for ADMA Biologics’ Q2 2019 earnings at ($0.26) EPS, Q3 2019 earnings at ($0.21) EPS, Q4 2019 earnings at ($0.20) EPS and FY2022 earnings at $0.68 EPS.

Get ADMA Biologics alerts:

ADMA has been the subject of several other research reports. ValuEngine raised ADMA Biologics from a “sell” rating to a “hold” rating in a research note on Monday, May 14th. Chardan Capital initiated coverage on ADMA Biologics in a research note on Monday, July 30th. They set a “buy” rating and a $10.00 target price for the company. Maxim Group set a $10.00 target price on ADMA Biologics and gave the stock a “buy” rating in a research note on Monday, May 14th. BidaskClub raised ADMA Biologics from a “hold” rating to a “buy” rating in a research note on Thursday, August 2nd. Finally, LADENBURG THALM/SH SH cut their target price on ADMA Biologics to $7.50 and set a “buy” rating for the company in a research note on Wednesday, June 13th. Seven analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and an average target price of $9.50.

Best Biotech Stocks To Watch Right Now: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Cory Renauer]

    What’s behind these dramatic gains? Read on to find out.

    Company Gain in H1 2018 Market Cap
    Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) 270% $1.19 billion
    ArQule, Inc. (NASDAQ:ARQL) 235% $482 million
    Endocyte, Inc. (NASDAQ:ECYT) 222% $959 million
    Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) 205% $3.99 billion

    Data source: YCharts.

  • [By Ethan Ryder]

    ArQule, Inc. (NASDAQ:ARQL) insider Value Fund L. P. Biotechnology sold 1,035,939 shares of the business’s stock in a transaction dated Wednesday, May 30th. The shares were sold at an average price of $5.00, for a total value of $5,179,695.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

  • [By Joseph Griffin]

    ArQule (NASDAQ:ARQL)‘s stock had its “buy” rating restated by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports. They currently have a $6.00 price target on the biotechnology company’s stock, up from their prior price target of $5.00. Needham & Company LLC’s price target suggests a potential upside of 134.38% from the company’s previous close.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on ArQule (ARQL)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Best Biotech Stocks To Watch Right Now: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Cory Renauer]

    The market for complex therapies that train living cells to attack cancer is taking baby steps, but there’s still a lot of enthusiasm for experimental drugs coming through the pipeline from bluebird bio (NASDAQ:BLUE) and it’s big biotech partner Celgene (NASDAQ:CELG). That enthusiasm fell a notch after Amgen (NASDAQ:AMGN) released exciting data from a handful of patients that suggests it’s found a much easier way to achieve the same goal. 

  • [By Max Byerly]

    Gables Capital Management Inc. purchased a new stake in Amgen, Inc. (NASDAQ:AMGN) during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 1,023 shares of the medical research company’s stock, valued at approximately $174,000.

  • [By Chris Lange]

    Amgen Inc. (NASDAQ: AMGN) is waiting for the FDA to review its Biologics License Application (BLA) for Aimovig (erenumab) for the prevention of migraine in patients experiencing four or more migraine days per month. The FDA has set a PDUFA date for May 17.

  • [By ]

    For example, if you buy 100 shares of the Nasdaq 100 ETF (NYSE: QQQ), you’re theoretically buying 11.9 shares of Apple (NASDAQ: AAPL)… 7.7 shares of Facebook (NASDAQ: FB)… 1.8 shares of Amgen (NASDAQ: AMGN)… 2.6 shares of Comcast (NASDAQ: CMCSA)… and even smaller amounts of about 95 different companies.

  • [By Cory Renauer]

    The Food and Drug Administration recently approved Aimovig from Amgen (NASDAQ:AMGN) and Novartis (NYSE:NVS), the first of several high-profile new drug candidates with a similar mode of action. Teva Pharmaceuticals Industries (NYSE:TEVA) and Eli Lilly (NYSE:LLY) have sent applications for similar drugs to the FDA and Alder’s starting to look like a terrier that showed up to a bullfight. 

Best Biotech Stocks To Watch Right Now: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By Sean Williams]

    Of course, my “bet against all Alzheimer’s drugs” thesis took a bit of a hit last week when biotech blue-chip Biogen (NASDAQ:BIIB), which is working alongside partner Eisai (NASDAQOTH:ESALY), reported positive mid-stage data on blockbuster hopeful BAN2401.

  • [By Steve Symington]

    But several individual stocks lagged the broader market. Read on to see why Cerner (NASDAQ:CERN), Biogen (NASDAQ:BIIB), and Alphabet (NASDAQ:GOOG)(NASDAQ:GOOGL) slumped today.

  • [By Cory Renauer]

    Healthcare is something that people need no matter what’s happening in the economy, so the sector is full of great stocks for investors seeking steadily growing income streams. That said, Abiomed, Inc. (NASDAQ:ABMD), Biogen Inc. (NASDAQ:BIIB), and Canopy Growth Corporation (NYSE:CGC) are three popular healthcare stocks that would make horrible additions to a retirement portfolio.

Best Biotech Stocks To Watch Right Now: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Brian Orelli]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) updated investors last month on how the launch of Onpattro, its first drug that was approved to treat transthyretin-mediated amyloidosis (ATTR), was going at the J.P. Morgan Healthcare Conference.

  • [By Shane Hupp]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lowered by equities research analysts at Morgan Stanley from $107.00 to $99.00 in a report released on Friday. The firm presently has an “equal weight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s price objective would indicate a potential upside of 3.97% from the stock’s current price.

  • [By Cory Renauer]

    Anyone who likes a good underdog story will want to keep their eye on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) and GW Pharmaceuticals PLC (NASDAQ:GWPH) through this year and next as they launch their first products in the U.S. Smaller biotechs have a terrible track record when it comes to launching new drugs on their own, but most analysts expect these companies to buck the trend and propel their recently approved drugs to blockbuster status within a few years.

  • [By Keith Speights]

    Speaking of competition, Ionis should have its hands full battling rivals for Tegsedi assuming the drug wins approval. Alnylam (NASDAQ:ALNY) anticipates winning FDA approval for its hATTR drug patisiran within a few weeks. Because the FDA delayed its decision on Tegsedi, Alnylam appears to be in position to reach the market first. In addition to its first-mover advantage, patisiran appears to have an edge over Tegsedi in efficacy and safety based on clinical data for the two drugs. 

Top 10 Biotech Stocks To Watch Right Now

Related WMT Will Walmart's International Segment Continue To Fuel Growth? Truckin': All The Tesla Semi Preorders So Far Target to Buy Delivery Service Shipt (GuruFocus)
Related ORCL Oracle Earnings Preview: Will Cloud Drive Growth Again? The Week Ahead: The Year's Biggest Biotech Conference, Host Of IPO Quiet Period Expirations, And Other Coming Catalysts Disney's Disturbance In The Force, Adobe Earnings: Investing Action Plan (Investor’s Business Daily)

On CNBC's "Fast Money Halftime Report", Jon Najarian spoke about high options volume in Wal-Mart Stores Inc (NYSE: WMT). When the stock was trading around $96.50, options traders were buying the February 100 calls aggressively. Najarian followed the trade and he is planning to hold it for two weeks.

Pete Najarian spoke about Oracle Corporation (NYSE: ORCL), which is due to report earnings Thursday. Around 7,500 contracts of the March 55 calls were traded in the first half of the session. The volume is unusual because it's much higher than the open interest.

Top 10 Biotech Stocks To Watch Right Now: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Cory Renauer]

    What’s behind these dramatic gains? Read on to find out.

    Company Gain in H1 2018 Market Cap
    Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) 270% $1.19 billion
    ArQule, Inc. (NASDAQ:ARQL) 235% $482 million
    Endocyte, Inc. (NASDAQ:ECYT) 222% $959 million
    Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) 205% $3.99 billion

    Data source: YCharts.

  • [By Lisa Levin] Gainers
    Melinta Therapeutics, Inc. (NASDAQ: MLNT) shares surged 20.6 percent to $6.39. WBB Securities upgraded Melinta Therapeutics from Hold to Speculative Buy.
    Shoe Carnival, Inc. (NASDAQ: SCVL) shares climbed 17.2 percent to $30.87 after the company reported upbeat quarterly earnings.
    Acorn International, Inc. (NYSE: ATV) shares rose 15.2 percent to $28.804 after the company declared a special one-time cash dividend of $14.97 per ADS.
    Foot Locker, Inc. (NYSE: FL) gained 15 percent to $53.35 after the company reported better-than-expected results for its first quarter.
    Sears Hometown and Outlet Stores, Inc. (NASDAQ: SHOS) surged 14.2 percent to $2.625.
    ArQule, Inc. (NASDAQ: ARQL) rose 13 percent to $5.12 after gaining 4.86 percent on Thursday.
    Quality Systems, Inc. (NASDAQ: QSII) gained 12.8 percent to $16.97 after the company posted better-than-expected FQ4 results.
    Loma Negra Compañía Industrial Argentina Sociedad Anónima (NYSE: LOMA) shares rose 12 percent to $12.94.
    ArQule, Inc. (NASDAQ: ARQL) shares rose 12 percent to $5.07.
    Mirati Therapeutics, Inc. (NASDAQ: MRTX) climbed 11.4 percent to $43.50.
    Zai Lab Limited (NASDAQ: ZLAB) gained 11.3 percent to $24.7000.
    Zymeworks Inc. (NASDAQ: ZYME) rose 9.7 percent to $19.64.
    Park City Group, Inc. (NASDAQ: PCYG) climbed 9 percent to $7.90.
    Roku, Inc. (NASDAQ: ROKU) gained 7.9 percent to $38.82 after Citron reversed previously bearish position on the stock.
    Sears Holdings Corporation (NASDAQ: SHLD) shares jumped 7.3 percent to $3.55.
    Deckers Outdoor Corp (NYSE: DECK) rose 3.5 percent to $107.27 after reporting better-than-expected results for its fiscal fourth quarter.

    Check out these big penny stock gainers and losers

  • [By Logan Wallace]

    ValuEngine downgraded shares of ArQule (NASDAQ:ARQL) from a strong-buy rating to a buy rating in a research report sent to investors on Saturday.

    Several other brokerages also recently issued reports on ARQL. Zacks Investment Research upgraded shares of ArQule from a hold rating to a buy rating and set a $2.75 target price for the company in a research note on Tuesday, May 8th. B. Riley set a $4.00 target price on shares of ArQule and gave the company a buy rating in a research note on Monday, March 26th. Roth Capital raised their target price on shares of ArQule from $5.00 to $6.00 and gave the company a buy rating in a research note on Tuesday, April 17th. BidaskClub upgraded shares of ArQule from a hold rating to a buy rating in a research note on Saturday, May 19th. Finally, Leerink Swann upgraded shares of ArQule from a market perform rating to an outperform rating in a research note on Thursday, April 5th. One research analyst has rated the stock with a sell rating, six have issued a buy rating and one has issued a strong buy rating to the company. The company has an average rating of Buy and a consensus price target of $5.35.

  • [By Maxx Chatsko]

    Shares of development-stage biopharma ArQule (NASDAQ:ARQL) rose nearly 17% today after the company announced two appointments to its management team in two newly created positions. Dr. Marc Schegerin will serve as senior vice president, corporate strategy, communication, and finance. Dr. Shirish Hirani will serve as senior vice president, program management and product planning. 

Top 10 Biotech Stocks To Watch Right Now: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Logan Wallace]

    Philadelphia Trust Co. decreased its holdings in Amgen, Inc. (NASDAQ:AMGN) by 8.0% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 74,676 shares of the medical research company’s stock after selling 6,501 shares during the quarter. Amgen makes up 1.2% of Philadelphia Trust Co.’s portfolio, making the stock its 22nd biggest position. Philadelphia Trust Co.’s holdings in Amgen were worth $13,784,000 as of its most recent SEC filing.

  • [By Stephan Byrd]

    Cpwm LLC increased its holdings in Amgen, Inc. (NASDAQ:AMGN) by 59.7% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,702 shares of the medical research company’s stock after purchasing an additional 3,253 shares during the period. Cpwm LLC’s holdings in Amgen were worth $1,606,000 at the end of the most recent quarter.

  • [By Todd Campbell]

    When a brand new class of cholesterol-lowering drugs called PCSK9 inhibitors won Food and Drug Administration (FDA) approval in 2015, it was heralded as the biggest advance in battling heart disease since the invention of statins. The launch of PCSK9 inhibitors was accompanied by billion-dollar-plus predictions for sales. However, revenue has fallen far shy of blockbuster status, leaving drugmakers Amgen Inc. (NASDAQ:AMGN), Regeneron Pharmaceuticals (NASDAQ:REGN), and Sanofi SA (NYSE:SNY) in the lurch.

  • [By Todd Campbell]

    Neulasta has been one of Amgen’s (NASDAQ:AMGN) crown jewels for years, but following FDA approval of Mylan’s (NASDAQ:MYL) Neulasta biosimilar this week, Amgen could see Neulasta’s revenue slow to a trickle. Is Mylan about to deliver a big blow to Amgen’s market share? Read on to find out what’s at stake for these companies and their investors.

  • [By Keith Speights]

    Amgen’s (NASDAQ:AMGN) past is filled with excitement. The company rose to become one of the biggest biotechs in the world. It grew a product lineup with multiple blockbuster drugs. Over the last decade, Amgen’s share price has more than tripled. But the excitement appears likely to diminish considerably for Amgen — at least for the next few years.

Top 10 Biotech Stocks To Watch Right Now: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Brian Orelli]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) updated investors last month on how the launch of Onpattro, its first drug that was approved to treat transthyretin-mediated amyloidosis (ATTR), was going at the J.P. Morgan Healthcare Conference.

  • [By Keith Speights]

    Speaking of competition, Ionis should have its hands full battling rivals for Tegsedi assuming the drug wins approval. Alnylam (NASDAQ:ALNY) anticipates winning FDA approval for its hATTR drug patisiran within a few weeks. Because the FDA delayed its decision on Tegsedi, Alnylam appears to be in position to reach the market first. In addition to its first-mover advantage, patisiran appears to have an edge over Tegsedi in efficacy and safety based on clinical data for the two drugs. 

  • [By Motley Fool Transcription]

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Q4 2019 Earnings Conference CallFeb. 7, 2017, 4:30 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Sean Williams, Chuck Saletta, and Brian Feroldi]

    So, which biotech stocks should you consider buying in June? That’s a question we posed to three of our healthcare-focused investors. Interestingly enough, mid-cap biotech stocks are the clear flavor of the month. If biotech is on your radar in June, our investors suggest you consider Ionis Pharmaceuticals (NASDAQ:IONS), Spark Therapeutics (NASDAQ:ONCE), and Alnylam Pharmaceuticals (NASDAQ:ALNY).

Top 10 Biotech Stocks To Watch Right Now: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By Chris Lange]

    Biogen Inc. (NASDAQ: BIIB) shares jumped early on Friday after the firm, in conjunction with Eisai out of Japan, announced positive results from a midstage Alzheimer’s study. The topline results came from the Phase 2 study with BAN2401, an anti-amyloid beta protofibril antibody, in 856 patients with early Alzheimer’s disease.

  • [By Chris Lange]

    Short interest in Biogen Inc. (NASDAQ: BIIB) decreased to 3.45 million shares from the previous 3.50 million. The stock recently traded at $274.50, within a 52-week range of $244.28 to $370.57.

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close was Biogen Inc. (NASDAQ: BIIB) which traded down over 5% at $288.75. The stock’s 52-week range is $249.17 to $370.57. Volume was 3.2 million compared to the daily average volume of 1.7 million.

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close Monday was Biogen Inc. (NASDAQ: BIIB) which traded down nearly 4% at $329.58. The stock’s 52-week range is $244.28 to $348.84. Volume was 1.2 million matching the daily average of 1.2 million shares.

  • [By Todd Campbell]

    Unfortunately for investors, June’s discovery wasn’t exciting enough for Sangamo partners Biogen (NASDAQ:BIIB) and Shire (NASDAQ:SHPG). In 2015, Biogen announced a delay to its beta-thalassemia and sickle-cell disease treatment program with Sangamo. And then Shire, a Sangamo collaboration partner since 2012, walked away from Sangamo’s hemophilia program.

Top Biotech Stocks To Buy Right Now

&l;p&g;Last month I found 37 mutual fund managers who have proved their skill (in my view) by outperforming the S&a;amp;P 500&a;nbsp;over the last decade by enough make a real difference for shareholders. Of these, 16 managers run funds that don&s;t charge a load and are still open to new investors.&a;nbsp; These are the managers I am using to&a;nbsp;demonstrate the results&a;nbsp;of investing with&a;nbsp;great managers when they are performing. The four managers I recommended at the end of June are off to a good start. But with a trade war looming, let&s;s make sure we have our money in the&a;nbsp;hands of the best managers.&l;/p&g;

&l;img class=&q;dam-image shutterstock wp-image-679141378 size-large&q; src=&q;https://specials-images.forbesimg.com/dam/imageserve/679141378/960×0.jpg?fit=scale&q; alt=&q;&q; data-height=&q;640&q; data-width=&q;960&q;&g; The greatest mutual fund managers. Shutterstock

&l;strong&g;Performance Review as of July 23, 2018&l;/strong&g;

&l;/p&g;&l;div class=&q;table-wrapper&q;&g;&l;table&g;&l;tbody&g;&l;tr&g;&l;th&g;Style&l;/th&g; &l;th&g;Fund&l;/th&g; &l;th&g;Symbol&l;/th&g; &l;th&g;Manager&l;/th&g; &l;th&g;July MTD Return&l;/th&g; &l;/tr&g;&l;tr&g;&l;td&g;Technology&l;/td&g; &l;td&g;Firsthand Technology Opportunities&l;/td&g; &l;td&g;TEFQX&l;/td&g; &l;td&g;Kevin Landis&l;/td&g; &l;td&g;3.42%&l;/td&g; &l;/tr&g;&l;tr&g;&l;td&g;Biotech&l;/td&g; &l;td&g;Fidelity Select Biotech&l;/td&g; &l;td&g;FBIOX&l;/td&g; &l;td&g;Rajiv Kaul&l;/td&g; &l;td&g;4.48%&l;/td&g; &l;/tr&g;&l;tr&g;&l;td&g;Healthcare&l;/td&g; &l;td&g;Delaware Healthcare I&l;/td&g; &l;td&g;DLHIX&l;/td&g; &l;td&g;Liu-Er Chen&l;/td&g; &l;td&g;3.22%&l;/td&g; &l;/tr&g;&l;tr&g;&l;td&g;Global Mid-Cap&l;/td&g; &l;td&g;Oppenheimer Global Opportunities&l;/td&g; &l;td&g;OGIYX&l;/td&g; &l;td&g;Frank V. Jennings&l;/td&g; &l;td&g;3.24%&l;/td&g; &l;/tr&g;&l;tr&g;&l;td&g;Benchmark&l;/td&g; &l;td&g;S&a;amp;P 500 ETF&l;/td&g; &l;td&g;SPY&l;/td&g; &l;td&g;&l;/td&g; &l;td&g;3.04%&l;/td&g; &l;/tr&g;&l;/tbody&g;&l;/table&g;&l;/div&g;

Top Biotech Stocks To Buy Right Now: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Stephan Byrd]

    ArQule, Inc. (NASDAQ:ARQL) Director Ronald M. Lindsay acquired 23,900 shares of the company’s stock in a transaction on Thursday, May 10th. The stock was acquired at an average price of $2.67 per share, for a total transaction of $63,813.00. Following the purchase, the director now directly owns 43,900 shares of the company’s stock, valued at $117,213. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

  • [By Ethan Ryder]

    ArQule, Inc. (NASDAQ:ARQL) insider Value Fund L. P. Biotechnology sold 1,035,939 shares of the business’s stock in a transaction dated Wednesday, May 30th. The shares were sold at an average price of $5.00, for a total value of $5,179,695.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

  • [By Cory Renauer]

    What’s behind these dramatic gains? Read on to find out.

    Company Gain in H1 2018 Market Cap
    Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) 270% $1.19 billion
    ArQule, Inc. (NASDAQ:ARQL) 235% $482 million
    Endocyte, Inc. (NASDAQ:ECYT) 222% $959 million
    Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) 205% $3.99 billion

    Data source: YCharts.

  • [By Joseph Griffin]

    ArQule (NASDAQ:ARQL)‘s stock had its “buy” rating restated by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports. They currently have a $6.00 price target on the biotechnology company’s stock, up from their prior price target of $5.00. Needham & Company LLC’s price target suggests a potential upside of 134.38% from the company’s previous close.

  • [By Logan Wallace]

    BidaskClub upgraded shares of ArQule (NASDAQ:ARQL) from a hold rating to a buy rating in a report released on Saturday.

    A number of other research firms have also issued reports on ARQL. Roth Capital upped their price target on ArQule from $5.00 to $6.00 and gave the company a buy rating in a research report on Tuesday, April 17th. Leerink Swann upgraded ArQule from a market perform rating to an outperform rating in a research report on Thursday, April 5th. Zacks Investment Research lowered ArQule from a buy rating to a hold rating in a research report on Wednesday, April 4th. ValuEngine upgraded ArQule from a hold rating to a buy rating in a research report on Wednesday, May 2nd. Finally, B. Riley set a $4.00 price target on ArQule and gave the company a buy rating in a research report on Monday, March 26th. Seven analysts have rated the stock with a buy rating, The stock currently has an average rating of Buy and an average target price of $4.69.

Top Biotech Stocks To Buy Right Now: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Chris Lange]

    Amgen Inc. (NASDAQ: AMGN) saw its short interest fall to 9.62 million shares from the previous level of 9.79 million. Shares were last seen at $178.26, in a 52-week trading range of $153.56 to $201.23.

  • [By ]

    Amgen (NASDAQ: AMGN) for example, announced FDA approval of its heart-attack prevention therapy on Dec 1. Immediately after, the stock popped 15% in less than two months, moving from $177.20 to $199.

  • [By Todd Campbell]

    Neulasta has been one of Amgen’s (NASDAQ:AMGN) crown jewels for years, but following FDA approval of Mylan’s (NASDAQ:MYL) Neulasta biosimilar this week, Amgen could see Neulasta’s revenue slow to a trickle. Is Mylan about to deliver a big blow to Amgen’s market share? Read on to find out what’s at stake for these companies and their investors.

Top Biotech Stocks To Buy Right Now: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By Lisa Levin]

    Analysts at Canaccord Genuity upgraded Biogen Inc. (NASDAQ: BIIB) from Hold to Buy.

    Biogen shares rose 2.55 percent to close at $294.40 on Tuesday.

  • [By Chris Lange]

    Ionis Pharmaceuticals Inc. (NASDAQ: IONS) shares made a handy gain on Friday after the firm announced an expanded strategic collaboration with Biogen Inc. (NASDAQ: BIIB). Through this partnership, these companies are planning to tackle and develop novel antisense drug candidates for a broad range of neurological diseases.

  • [By Keith Speights]

    Three biotech stocks that achieved this feat this week are Nightstar Therapeutics (NASDAQ:NITE), Arbutus Biopharma (NASDAQ:ABUS), and Biogen (NASDAQ:BIIB). What caused these stocks to soar, and are they smart picks to buy now? Here’s what you need to know.

  • [By Chris Lange]

    Short interest in Biogen Inc. (NASDAQ: BIIB) increased to 4.00 million shares from the previous 3.91 million. The stock recently traded at $346.90, within a 52-week range of $249.17 to $388.67.

  • [By Chris Lange]

    Short interest in Biogen Inc. (NASDAQ: BIIB) increased to 4.73 million shares from the previous 4.33 million. The stock recently traded at $291.92, within a 52-week range of $249.17 to $370.57.

  • [By Keith Speights]

    This has been a bad year for Biogen (NASDAQ:BIIB) so far — the biotech’s stock has dropped more than 10% since it began. But 2018 has been horrible for Acadia Pharmaceuticals (NASDAQ:ACAD), which has seen its share price plunge nearly 40%.

Top Biotech Stocks To Buy Right Now: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Brian Orelli]

    The delay in an FDA decision for Tegsedi puts it behind competitor Alnylam Pharmaceuticals (NASDAQ:ALNY), which expects to hear from the FDA by Aug. 11 for its hATTR drug patisiran. But Sarah Boyce, the president at Akcea Therapeutics, doesn’t think a few months will really matter: “We don’t really feel that’s going to have any impact and the drugs will be close enough together from a launch perspective. So not really [going] to make any adjustments, and we’re very well prepared to be ready to launch following approval.”

  • [By Cory Renauer]

    Anyone who likes a good underdog story will want to keep their eye on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) and GW Pharmaceuticals PLC (NASDAQ:GWPH) through this year and next as they launch their first products in the U.S. Smaller biotechs have a terrible track record when it comes to launching new drugs on their own, but most analysts expect these companies to buck the trend and propel their recently approved drugs to blockbuster status within a few years.

  • [By Ethan Ryder]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by stock analysts at ValuEngine from a “buy” rating to a “hold” rating in a report released on Tuesday.

  • [By Todd Campbell]

    Spark Therapeutics (NASDAQ:ONCE) reported its hemophilia A drug significantly reduced bleeding events and the need for prophylactic factor VIII infusions, but investors sold shares on worry that the gene therapy’s safety could be a problem. Investors similarly headed for the exits with Rite Aid (NYSE:RAD) and Alnylam Pharmaceuticals (NASDAQ:ALNY) after the former scuttled an attempt to sell itself and the latter secured a first-in-class FDA approval. Are these falling stocks worth buying?

  • [By Shane Hupp]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lowered by equities research analysts at Morgan Stanley from $107.00 to $99.00 in a report released on Friday. The firm presently has an “equal weight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s price objective would indicate a potential upside of 3.97% from the stock’s current price.

  • [By Max Byerly]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($1.41) EPS for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.06. The business had revenue of $21.90 million during the quarter, compared to analysts’ expectations of $35.23 million. Alnylam Pharmaceuticals had a negative return on equity of 36.81% and a negative net margin of 565.20%. The business’s quarterly revenue was up 15.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.25) earnings per share. equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -6.7 earnings per share for the current fiscal year.

Top 10 High Tech Stocks To Watch For 2019

Pattern Energy Group Inc. (NASDAQ:PEGI) offers investors an impressive 8.4% yield. That sounds like a pretty rewarding way for income investors to invest in renewable power, which is the company’s focus. In fact, it makes renewable-power peer Brookfield Renewable Partners LP’s (NYSE:BEP) yield of 6.3% look small by comparison. But don’t chase that higher yield until you read this, because you’re likely to decide that Brookfield Renewable Partners, despite having a lower yield, is the better dividend stock.

Thanks, Mom and Dad

Both Pattern Energy Group and Brookfield Renewable Partners have parents that oversee them. This relationship is most clear in the case of Brookfield Renewable Partners, which is run by Canadian alternative asset manager Brookfield Asset Management (NYSE:BAM), its general partner. This giant asset manager, with more than 100 years of history behind it and roughly $290 billion in assets under management, basically oversees day-to-day operations, sources acquisitions, and even helps provide funding (it has a roughly 60% stake in the partnership).

Top 10 High Tech Stocks To Watch For 2019: Partner Communications Company Ltd.(PTNR)

Advisors’ Opinion:

  • [By Lisa Levin]

    Thursday morning, the telecommunication services shares rose 1.06 percent. Meanwhile, top gainers in the sector included Globalstar, Inc. (NYSE: GSAT), up 5 percent, and Partner Communications Company Ltd. (NASDAQ: PTNR) up 4 percent.

  • [By Logan Wallace]

    Deutsche Telekom (OTCMKTS: DTEGY) and Partner Communications (NASDAQ:PTNR) are both utilities companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

  • [By Motley Fool Transcribers]

    Partner Communications Company Ltd. (NASDAQ:PTNR)Q2 2018 Earnings Conference CallAug. 15, 2018, 10:00 a.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

Top 10 High Tech Stocks To Watch For 2019: Tree.com Inc.(TREE)

Advisors’ Opinion:

  • [By Dan Caplinger]

    The stock market climbed sharply on Thursday, responding well to favorable earnings results from several corners of the market. Major benchmarks were up 1% to 2%, with particularly good performance from the Nasdaq Composite thanks to the tech sector’s outperformance during the day. Yet some stocks suffered from bad news that cast doubt on companies’ ability to benefit from generally favorable business conditions. MGM Resorts International (NYSE:MGM), Arch Coal (NYSE:ARCH), and LendingTree (NASDAQ:TREE) were among the worst performers on the day. Here’s why they did so poorly.

  • [By Logan Wallace]

    Rhumbline Advisers decreased its position in LendingTree (NASDAQ:TREE) by 13.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,988 shares of the financial services provider’s stock after selling 2,252 shares during the period. Rhumbline Advisers’ holdings in LendingTree were worth $4,590,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Lendingtree (TREE)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Demitrios Kalogeropoulos]

    Shares of consumer lending specialist LendingTree (NASDAQ:TREE) spiked 35% last month, trouncing the S&P 500’s 8% gain, according to data provided by S&P Global Market Intelligence.

Top 10 High Tech Stocks To Watch For 2019: Innodata Inc.(INOD)

Advisors’ Opinion:

  • [By Logan Wallace]

    Luzich Partners LLC lifted its stake in shares of Innodata Inc (NASDAQ:INOD) by 4.9% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,316,550 shares of the technology company’s stock after acquiring an additional 61,944 shares during the period. Innodata accounts for approximately 1.5% of Luzich Partners LLC’s portfolio, making the stock its 12th biggest position. Luzich Partners LLC owned about 5.09% of Innodata worth $1,514,000 at the end of the most recent reporting period.

  • [By Stephan Byrd]

    Media coverage about Innodata (NASDAQ:INOD) has trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Innodata earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave news articles about the technology company an impact score of 47.3485759085159 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

  • [By Stephan Byrd]

    Innodata (NASDAQ:INOD) will be releasing its Q1 2018 earnings data before the market opens on Tuesday, May 8th.

    Innodata (NASDAQ:INOD) last announced its earnings results on Thursday, March 8th. The technology company reported ($0.02) earnings per share (EPS) for the quarter. The business had revenue of $15.66 million for the quarter. Innodata had a negative return on equity of 10.94% and a negative net margin of 8.30%.

Top 10 High Tech Stocks To Watch For 2019: Marathon Oil Corporation(MRO)

Advisors’ Opinion:

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage gain ahead of the close was Marathon Oil Corp. (NYSE: MRO) which traded up about 5% at $21.81. The stock’s 52-week range is $10.64 to $22.74. Volume was nearly 16 million compared to the daily average volume of 11 million.

  • [By Matthew DiLallo]

    Saudi Aramco’s valuation, however, isn’t the only one that would benefit from a pop in the price of crude. Many oil producers in the U.S. restructured their operations to run on $50 oil, so if the Saudi strategy is successful, these oil companies would produce a gusher of cash flow, which could fuel high-octane gains for investors. While that rise would likely lift the entire sector, Devon Energy (NYSE:DVN) and Marathon Oil (NYSE:MRO) could outperform in that scenario.

  • [By Tyler Crowe]

    Back in 2011, Marathon Oil (NYSE:MRO) elected to spin off Marathon Petroleum. At the time, much of the reasoning for the split was that both entities would garner higher valuations than as an integrated company. Also, by separating them, both could best allocate capital to grow shareholder value. 

Top 10 High Tech Stocks To Watch For 2019: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By Benzinga News Desk]

    A distillery in a small Spanish town has claimed it invented the original Coca-Cola (NYSE: KO) recipe and now wants recognition: Link

    ECONOMIC DATA
    Initial Jobless Claims For Week Ended May 25 221K vs 225K Economist Estimate, Down From 234K In Prior Week
    Personal Income Apr. Up 0.3%, Personal Spending Up 0.6%
    The Chicago PMI for May is schedule for release at 9:45 a.m. ET.
    The pending home sales index for April will be released at 10:00 a.m. ET.
    The Energy Information Administration’s weekly report on natural gas stocks in underground storage is schedule for release at 10:30 a.m. ET.
    The Energy Information Administration’s weekly report on petroleum inventories will be released at 11:00 a.m. ET.
    Federal Reserve Bank of Atlanta President Raphael Bostic is set to speak at 12:30 p.m. ET.
    Fed Governor Lael Brainard will speak at 1:00 p.m. ET.
    Data on money supply for the recent week will be released at 4:30 p.m. ET.
    Federal Reserve Bank of Dallas President Robert Kaplan is set to speak at 8:30 p.m. ET.
    ANALYST RATINGS
    Canaccord upgrades Biogen (NASDAQ: BIIB) from Hold to Buy
    Morgan Stanley upgrades Corning (NYSE: GLW) from Equal-Weight to Overweight
    Morgan Stanley downgrades Micron (NASDAQ: MU) from Overweight to Equal-Weight
    Cantor downgrades HealthEquity (NASDAQ: HQY) from Overweight to Neutral

    This is a tool used by the Benzinga News Desk each trading day — it's a look at everything happening in the market, in five minutes. To get the full version of this note every morning, click here.

  • [By Joseph Griffin]

    Rhenman & Partners Asset Management AB lifted its holdings in shares of Biogen Inc (NASDAQ:BIIB) by 130.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 30,000 shares of the biotechnology company’s stock after purchasing an additional 17,000 shares during the quarter. Rhenman & Partners Asset Management AB’s holdings in Biogen were worth $10,599,000 as of its most recent filing with the Securities and Exchange Commission.

  • [By Cory Renauer]

    Biogen Inc. (NASDAQ:BIIB) and Gilead Sciences, Inc. (NASDAQ:GILD) were two of biotech’s best-performing stocks in years past, but investors are a lot more worried about where they’re going right now. Gilead Sciences has a new management team and a new focus on treating cancer. Now that competitors have diminished Biogen’s dominance in the multiple sclerosis space, the company’s taking bold steps as well.

  • [By ]

    What should investors do with shares of Celgene (CELG) , Biogen Idec (BIIB) , Gilead Science (GILD) and Regeneron (REGN) ? Cramer once proclaimed these high-fliers his “four horsemen of biotech,” but lately they’ve lost all of their traction, with Celgene down 21%, Biogen off 14%, Gilead down 9% and Regeneron off 23% so far this year.

Top 10 High Tech Stocks To Watch For 2019: StoneMor Partners L.P.(STON)

Advisors’ Opinion:

  • [By WWW.GURUFOCUS.COM]

    For the details of AXAR CAPITAL MANAGEMENT L.P.’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=AXAR+CAPITAL+MANAGEMENT+L.P.

    These are the top 5 holdings of AXAR CAPITAL MANAGEMENT L.P.Stonemor Partners LP (STON) – 6,650,613 shares, 68.21% of the total portfolio. Shares added by 8.91%Patterson-UTI Energy Inc (PTEN) – 730,000 shares, 21.11% of the total portfolio. Stage Stores Inc (SSI) – 1,750,000 shares, 6.3% of the total portfolio. Shares added by 75.00%Five Star Senior Living Inc (FVE) – 2,039,878 shares, 4.38% of the total portfolio. Added

  • [By Joseph Griffin]

    StoneMor Partners L.P. (NYSE:STON) major shareholder Axar Capital Management L.P. purchased 6,420 shares of StoneMor Partners stock in a transaction that occurred on Monday, September 17th. The shares were purchased at an average cost of $4.34 per share, with a total value of $27,862.80. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Top 10 High Tech Stocks To Watch For 2019: Murphy Oil Corporation(MUR)

Advisors’ Opinion:

  • [By Max Byerly]

    Shares of Murphy Oil Co. (NYSE:MUR) have earned an average recommendation of “Hold” from the thirteen ratings firms that are currently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have assigned a buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $33.11.

  • [By Shane Hupp]

    Murphy Oil Co. (NYSE:MUR) saw some unusual options trading activity on Wednesday. Stock investors purchased 1,420 put options on the company. This is an increase of 1,929% compared to the average volume of 70 put options.

  • [By Logan Wallace]

    Texas Permanent School Fund cut its holdings in Murphy Oil Co. (NYSE:MUR) by 2.2% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 104,981 shares of the oil and gas producer’s stock after selling 2,410 shares during the period. Texas Permanent School Fund owned approximately 0.06% of Murphy Oil worth $3,545,000 as of its most recent filing with the Securities and Exchange Commission.

  • [By Logan Wallace]

    Clinton Group Inc. purchased a new stake in Murphy Oil Co. (NYSE:MUR) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 14,491 shares of the oil and gas producer’s stock, valued at approximately $489,000.

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Murphy Oil (MUR)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 High Tech Stocks To Watch For 2019: Franklin Universal Trust(FT)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Fabric Token (CURRENCY:FT) traded down 14.3% against the dollar during the one day period ending at 16:00 PM E.T. on September 12th. Over the last week, Fabric Token has traded 11.8% higher against the dollar. Fabric Token has a total market cap of $266,502.00 and approximately $105.00 worth of Fabric Token was traded on exchanges in the last 24 hours. One Fabric Token token can now be bought for approximately $0.0108 or 0.00000171 BTC on major cryptocurrency exchanges including IDEX and Cryptopia.

  • [By Logan Wallace]

    Fabric Token (CURRENCY:FT) traded down 5.2% against the dollar during the 1-day period ending at 19:00 PM Eastern on August 14th. Fabric Token has a market capitalization of $352,990.00 and $1,545.00 worth of Fabric Token was traded on exchanges in the last day. One Fabric Token token can currently be purchased for approximately $0.0144 or 0.00000232 BTC on major cryptocurrency exchanges including Cryptopia and IDEX. In the last seven days, Fabric Token has traded down 49.9% against the dollar.

Top 10 High Tech Stocks To Watch For 2019: Dave & Buster's Entertainment, Inc.(PLAY)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Brokerages expect Dave & Buster’s Entertainment Inc (NASDAQ:PLAY) to announce sales of $311.08 million for the current quarter, Zacks Investment Research reports. Six analysts have provided estimates for Dave & Buster’s Entertainment’s earnings. The highest sales estimate is $318.70 million and the lowest is $299.70 million. Dave & Buster’s Entertainment reported sales of $280.75 million in the same quarter last year, which indicates a positive year over year growth rate of 10.8%. The firm is expected to issue its next earnings report on Tuesday, September 4th.

  • [By Demitrios Kalogeropoulos]

    Investors have been hoping that a management shakeup and new turnaround plan would get things rolling again at Dave & Buster’s (NASDAQ:PLAY). Yet the restaurant/entertainment chain had a deep hole to climb out of after sales missed expectations in the fiscal first quarter.

  • [By Logan Wallace]

    Dynamic Technology Lab Private Ltd acquired a new position in shares of Dave & Buster’s Entertainment Inc (NASDAQ:PLAY) in the second quarter, Holdings Channel reports. The fund acquired 45,243 shares of the restaurant operator’s stock, valued at approximately $2,154,000.

Top 10 High Tech Stocks To Watch For 2019: Trustmark Corporation(TRMK)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Trustmark (TRMK)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    Rhumbline Advisers lowered its position in Trustmark Corp (NASDAQ:TRMK) by 5.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 122,924 shares of the financial services provider’s stock after selling 7,773 shares during the quarter. Rhumbline Advisers owned about 0.18% of Trustmark worth $3,830,000 at the end of the most recent quarter.

  • [By Joseph Griffin]

    Trustmark (NASDAQ: TRMK) and Valley National Bank (NYSE:VLY) are both mid-cap finance companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk and earnings.

Top Biotech Stocks To Own Right Now

&l;p&g;Andreas Halvorsen&a;rsquo;s Viking Global Investors disclosed Thursday that it holds a 75.6% stake in urologic biopharmaceutical company Urovant Sciences Ltd. through its private backing of the company&a;rsquo;s parent.

&l;img class=&q;dam-image bloomberg size-large wp-image-39175851&q; src=&q;https://specials-images.forbesimg.com/dam/imageserve/39175851/960×0.jpg?fit=scale&q; data-height=&q;640&q; data-width=&q;960&q;&g; Andreas Halvorsen, chief executive officer of Viking Global Investors LP, made one of the largest-ever private equity biotech investments in the parent company of Urovant. Photographer: David Paul Morris/Bloomberg

Halvorsen made the holding known because Urovant went public on Oct. 1. The company originated as one of 13 &a;ldquo;Vants&a;rdquo; developed by umbrella owner Roivant Sciences. Each &a;ldquo;Vant&a;rdquo; focuses on research, development and commercialization of treatments for a specified disease. Founded by Vivek Ramaswamy in 2014, the Switzerland-based Riovant often acquires promising drugs discarded by larger biopharmaceutical companies.

Top Biotech Stocks To Own Right Now: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Keith Speights]

    It’s not exactly David vs. Goliath. However, Bellicum Pharmaceuticals (NASDAQ:BLCM) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are definitely in different leagues right now. Both are clinical-stage biotechs, but Bellicum’s market cap is less than $350 million while Alnylam’s market cap is close to $10 billion.

  • [By Cory Renauer]

    Anyone who likes a good underdog story will want to keep their eye on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) and GW Pharmaceuticals PLC (NASDAQ:GWPH) through this year and next as they launch their first products in the U.S. Smaller biotechs have a terrible track record when it comes to launching new drugs on their own, but most analysts expect these companies to buck the trend and propel their recently approved drugs to blockbuster status within a few years.

  • [By Joseph Griffin]

    Northern Trust Corp lifted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 4.4% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 492,768 shares of the biopharmaceutical company’s stock after purchasing an additional 20,992 shares during the period. Northern Trust Corp owned about 0.49% of Alnylam Pharmaceuticals worth $48,533,000 at the end of the most recent quarter.

Top Biotech Stocks To Own Right Now: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Ethan Ryder]

    ArQule, Inc. (NASDAQ:ARQL) insider Value Fund L. P. Biotechnology sold 1,035,939 shares of the business’s stock in a transaction dated Wednesday, May 30th. The shares were sold at an average price of $5.00, for a total value of $5,179,695.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

  • [By Logan Wallace]

    ValuEngine downgraded shares of ArQule (NASDAQ:ARQL) from a strong-buy rating to a buy rating in a research report sent to investors on Saturday.

    Several other brokerages also recently issued reports on ARQL. Zacks Investment Research upgraded shares of ArQule from a hold rating to a buy rating and set a $2.75 target price for the company in a research note on Tuesday, May 8th. B. Riley set a $4.00 target price on shares of ArQule and gave the company a buy rating in a research note on Monday, March 26th. Roth Capital raised their target price on shares of ArQule from $5.00 to $6.00 and gave the company a buy rating in a research note on Tuesday, April 17th. BidaskClub upgraded shares of ArQule from a hold rating to a buy rating in a research note on Saturday, May 19th. Finally, Leerink Swann upgraded shares of ArQule from a market perform rating to an outperform rating in a research note on Thursday, April 5th. One research analyst has rated the stock with a sell rating, six have issued a buy rating and one has issued a strong buy rating to the company. The company has an average rating of Buy and a consensus price target of $5.35.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on ArQule (ARQL)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    ArQule, Inc. (NASDAQ:ARQL)’s share price rose 6.2% during trading on Thursday . The stock traded as high as $5.21 and last traded at $5.15. Approximately 955,706 shares changed hands during mid-day trading, a decline of 23% from the average daily volume of 1,244,948 shares. The stock had previously closed at $4.85.

  • [By Joseph Griffin]

    ArQule (NASDAQ:ARQL)‘s stock had its “buy” rating restated by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports. They currently have a $6.00 price target on the biotechnology company’s stock, up from their prior price target of $5.00. Needham & Company LLC’s price target suggests a potential upside of 134.38% from the company’s previous close.

Top Biotech Stocks To Own Right Now: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close was Biogen Inc. (NASDAQ: BIIB) which traded down over 5% at $288.75. The stock’s 52-week range is $249.17 to $370.57. Volume was 3.2 million compared to the daily average volume of 1.7 million.

  • [By Stephan Byrd]

    Traders bought shares of Biogen Inc (NASDAQ:BIIB) on weakness during trading on Tuesday. $119.44 million flowed into the stock on the tick-up and $86.88 million flowed out of the stock on the tick-down, for a money net flow of $32.56 million into the stock. Of all companies tracked, Biogen had the 26th highest net in-flow for the day. Biogen traded down ($7.15) for the day and closed at $345.41

  • [By Joseph Griffin]

    Rhenman & Partners Asset Management AB lifted its holdings in shares of Biogen Inc (NASDAQ:BIIB) by 130.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 30,000 shares of the biotechnology company’s stock after purchasing an additional 17,000 shares during the quarter. Rhenman & Partners Asset Management AB’s holdings in Biogen were worth $10,599,000 as of its most recent filing with the Securities and Exchange Commission.

  • [By Logan Wallace]

    Biogen Inc (NASDAQ:BIIB) EVP Michael D. Ehlers sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, September 26th. The stock was sold at an average price of $350.00, for a total value of $350,000.00. Following the completion of the transaction, the executive vice president now owns 4,281 shares of the company’s stock, valued at $1,498,350. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Biogen (BIIB)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top Biotech Stocks To Own Right Now: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Keith Speights]

    Amgen (NASDAQ:AMGN) and Gilead Sciences (NASDAQ:GILD) rank among the elite in the world of biotech. Both companies have long track records of success. Both generate huge cash flow, but both also face headwinds.

  • [By Todd Campbell]

    When a brand new class of cholesterol-lowering drugs called PCSK9 inhibitors won Food and Drug Administration (FDA) approval in 2015, it was heralded as the biggest advance in battling heart disease since the invention of statins. The launch of PCSK9 inhibitors was accompanied by billion-dollar-plus predictions for sales. However, revenue has fallen far shy of blockbuster status, leaving drugmakers Amgen Inc. (NASDAQ:AMGN), Regeneron Pharmaceuticals (NASDAQ:REGN), and Sanofi SA (NYSE:SNY) in the lurch.

  • [By Max Byerly]

    Gables Capital Management Inc. purchased a new stake in Amgen, Inc. (NASDAQ:AMGN) during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 1,023 shares of the medical research company’s stock, valued at approximately $174,000.

Top 5 Biotech Stocks To Own For 2019

Piper Jaffray’s Joshua Schimmer and team offer their take on the Biogen (BIIB) takeover speculation that sent shares of the biotech giant soaring this afternoon:

Bloomberg News/Scott Eisen

Biogen shares are trading higher on a WSJ report which indicates the company may have interest from prospective pharma buyers. The WSJ is one of the more credible sources for such speculation and is often a publication used to put companies ‘in play’, we believe. Because of its higher bar for sourcing M&A interest such as this, we think the report is a strategy being used to catalyze a potential deal. That said, we believe there are a number of challenges to be overcome for any transaction to materialize. As we have noted recently our outlook on BIIB is more optimistic, and there is now a new dynamic to the investment opportunity…

Top 5 Biotech Stocks To Own For 2019: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Logan Wallace]

    Intact Investment Management Inc. grew its holdings in Amgen (NASDAQ:AMGN) by 2,737.5% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 45,400 shares of the medical research company’s stock after purchasing an additional 43,800 shares during the period. Intact Investment Management Inc.’s holdings in Amgen were worth $7,739,000 as of its most recent filing with the Securities & Exchange Commission.

  • [By Jon C. Ogg]

    In September of 2016, Amgen Inc. (NASDAQ: AMGN) announced that the FDA had approved its Amjevita as a biosimilar to Humira for multiple inflammatory diseases that included RA and several other related inflammatory diseases.

  • [By ]

    Amgen (NASDAQ: AMGN) for example, announced FDA approval of its heart-attack prevention therapy on Dec 1. Immediately after, the stock popped 15% in less than two months, moving from $177.20 to $199.

  • [By Keith Speights]

    Amgen (NASDAQ:AMGN) and Gilead Sciences (NASDAQ:GILD) rank among the elite in the world of biotech. Both companies have long track records of success. Both generate huge cash flow, but both also face headwinds.

Top 5 Biotech Stocks To Own For 2019: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By Chris Lange]

    Biogen Inc.’s (NASDAQ: BIIB) second-quarter report is scheduled for Tuesday before the markets open. The consensus estimates are $5.24 in earnings per share (EPS) on $3.26 billion in revenue. The shares ended the week trading at $357.56. The consensus price target is $367.08, and the 52-week trading range is $249.17 to $370.57.

  • [By Garrett Baldwin]

    Markets are keeping a close eye on the 10-year bond, which is hovering near 3% – an important psychological level that is likely to influence future price movements. On Monday, Fox Business Network’s “Varney & Co.” asked Money Morning Chief Investment Strategist Keith Fitz-Gerald if investors should be worried. Here’s what Keith had to say about the 10-year Treasury yield… and how it will affect your stocks and bonds in the future.
    The price of Brent crude oil topped $75.00 and hit its highest level since November 2014. Oil traders were eyeing the ongoing efforts of OPEC and Russia to reduce excessive production around the globe, rising demand ahead of peak driving season, and the possibility that the Trump administration will slap Iran with a new round of sanctions.
    Three Stocks to Watch Today: KO, GOOGL, SLM
    Shares of The Coca-Cola Co. (NYSE: KO) added 1.2% after the firm easily beat earnings and revenue expectations. The firm cited strong demand for its new flavors of Diet Coke and its Coke Zero Sugar. Demand was so strong for the quarter that the firm reported organic sales growth of 5%. The company reported earnings per share of $0.47, topping estimates by a penny. Revenue of $7.6 billion easily beat Wall Street estimates.
    Shares of Alphabet Inc. (Nasdaq: GOOGL) seesawed in pre-market hours. The online search giant topped Wall Street earnings and revenue expectations after the bell Monday. However, shares were off 0.5% after executives announced that its business costs were on the rise. The firm’s real estate and computer purchases tripled in one year, to $7.3 billion. About one-third of that total came from its $2.4 billion purchase of the Chelsea Market building in New York City.
    Good news for SLM Corp. (NYSE: SLM) investors, but bad news for indebted college students and graduates. The firm – also known as Sallie Mae – topped Wall Street earnings expectations on Monday. The firm said that it increased its loan o

  • [By Todd Campbell]

    PTC Therapeutics (NASDAQ:PTCT) shares took off after updated data from a trial evaluating risdiplam suggested it could mount a stiff challenge to Biogen’s (NASDAQ:BIIB) and Ionis Pharmaceuticals’ (NASDAQ:IONS) Spinraza for the treatment of  spinal muscular atrophy (SMA), a rare and life-threatening genetic disease. The data is solid, but a one-and-done SMA treatment is already in late-stage studies at Novartis’ (NYSE:NVS), and that therapy could become available as soon as 2019. 

  • [By Cory Renauer]

    Healthcare is something that people need no matter what’s happening in the economy, so the sector is full of great stocks for investors seeking steadily growing income streams. That said, Abiomed, Inc. (NASDAQ:ABMD), Biogen Inc. (NASDAQ:BIIB), and Canopy Growth Corporation (NYSE:CGC) are three popular healthcare stocks that would make horrible additions to a retirement portfolio.

  • [By George Budwell]

    Shares of large-cap biotech Biogen (NASDAQ:BIIB) gained a healthy 15.2% in July, according to data from S&P Global Market Intelligence. What triggered this breakout? 

  • [By Cory Renauer]

    Ionis still has a 75% stake in Akcea, but Waylivra’s CRL is more of a speed bump than a roadblock for the RNA antisense pioneer. Investors probably don’t need to worry about potential partners avoiding Ionis because of Waylivra’s mishap. Spinraza, an Ionis drug that Biogen (NASDAQ:BIIB) launched at the end of 2016, hit an annualized $1.7 billion run rate in the second quarter.

Top 5 Biotech Stocks To Own For 2019: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Logan Wallace]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Although Alnylam has a broad and promising pipeline, we note that most candidates are in mid stages of development. These candidates still have a long way to go before hitting the market. The company relies highly on collaborators for funding. Any development/regulatory setback would be a negative for the company.  However, Alnylam reported positive data from the ATLAS study in the first quarter which led to regulatory filings for its late-stage pipeline candidate patisiran and the FDA set an action date of Aug 11, 2018. The company along with its partners Sanofi and The Medicines Company, restarted fitusiran's ATLAS phase III study and advanced inclisiran in the ORION-9, -10, and -11 phase III studies, respectively, with results expected for both programs in 2019. Alnylam expects to achieve the profile of three marketed products by the end of 2020.”

  • [By Motley Fool Transcription]

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Q4 2019 Earnings Conference CallFeb. 7, 2017, 4:30 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Jim Crumly]

    Drug giant Pfizer released details of a successful trial of a drug for heart damage from a rare disease, and although that company’s stock had little reaction, falling 1.9%, shares of companies with potentially competing drugs reacted sharply. Alnylam Pharmaceuticals (NASDAQ:ALNY) soared 16.2%, Ionis Pharmaceuticals (NASDAQ:IONS) jumped 7.8%, and Eidos Therapeutics (NASDAQ:EIDX) plunged 31.1%.

  • [By Brian Orelli]

    Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) were up 19% at 12:04 p.m. EDT on Monday after rival Pfizer (NYSE:PFE) released data for its transthyretin amyloid (ATTR) drug tafamidis at the ESC Congress 2018, which were also published in the New England Journal of Medicine. Earlier this month, Alnylam got its ATTR drug, Onpattro, approved by the Food and Drug Administration. Shares of Ionis Pharmaceuticals (NASDAQ:IONS) and Akcea Therapeutics (NASDAQ:AKCA), which are jointly developing another ATTR drug, Tegsedi, are up 10% and 2.6% respectively.

Top 5 Biotech Stocks To Own For 2019: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Joseph Griffin]

    ValuEngine upgraded shares of ArQule (NASDAQ:ARQL) from a buy rating to a strong-buy rating in a research report released on Tuesday.

    Several other equities analysts have also issued reports on ARQL. Zacks Investment Research upgraded ArQule from a hold rating to a buy rating and set a $2.50 price objective for the company in a research report on Tuesday, March 20th. BidaskClub upgraded ArQule from a buy rating to a strong-buy rating in a research report on Saturday, March 24th. B. Riley set a $4.00 price objective on ArQule and gave the company a buy rating in a research report on Monday, March 26th. Leerink Swann upgraded ArQule from a market perform rating to an outperform rating in a research report on Thursday, April 5th. Finally, Roth Capital boosted their price objective on ArQule from $5.00 to $6.00 and gave the company a buy rating in a research report on Tuesday, April 17th. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and two have issued a strong buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $5.35.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on ArQule (ARQL)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on ArQule (ARQL)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Lisa Levin] Gainers
    Foot Locker, Inc. (NYSE: FL) rose 15.3 percent to $53.50 in pre-market trading after the company reported better-than-expected results for its first quarter.
    Evofem Biosciences, Inc. (NASDAQ: EVFM) rose 10.4 percent to $4.58 in pre-market trading. Evofem Biosciences reported closing of public offering of common stock and warrants.
    Resonant Inc. (NASDAQ: RESN) rose 7.3 percent to $4.88 in pre-market trading after declining 1.94 percent on Thursday.
    SolarEdge Technologies, Inc. (NASDAQ: SEDG) shares rose 5.7 percent to $59.65 in pre-market trading after falling 8.43 percent on Thursday.
    Yirendai Ltd. (NYSE: YRD) rose 5 percent to $30.00 in pre-market trading after reporting Q1 results.
    Deckers Outdoor Corp (NYSE: DECK) rose 4.9 percent to $108.75 in pre-market trading after reporteingd better-than-expected results for its fiscal fourth quarter.
    Blue Apron Holdings, Inc. (NYSE: APRN) rose 4.2 percent to $3.21 in pre-market trading after gaining 3.70 percent on Thursday.
    Recro Pharma, Inc. (NASDAQ: REPH) rose 4 percent to $5.85 in pre-market trading after dropping 54.67 percent on Thursday.
    ArQule, Inc. (NASDAQ: ARQL) rose 3.8 percent to $4.70 in pre-market trading after gaining 4.86 percent on Thursday.
    Babcock & Wilcox Enterprises, Inc. (NYSE: BW) shares rose 2.9 percent to $2.85 in pre-market trading after climbing 7.78 percent on Thursday.
    Bilibili Inc. (NASDAQ: BILI) shares rose 2.5 percent to $14.20 in pre-market trading after surging 11.33 percent on Thursday.

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

  • [By Money Morning Staff Reports]

    But Blink and our other penny stocks to watch are unlikely to continue to lock in such spectacular gains in June. After looking at our 10 top penny stocks to watch this month, we’ll show you a small-cap stock with great profit potential in its future…

    Penny Stock Current Share Price Law Month’s Gain
     Blink Charging Co. (Nasdaq: BLNK) $7.07 439.85%
    Senes Tech Inc. (Nasdaq: SNES) $1.27 175.40%
    Vivis Inc. (Nasdaq: VVUS) $0.77 150.41%
    Adomani Inc. (Nasdaq: ADOM) $1.49 137.68%
    NF Energy Saving Co. (Nasdaq: NFEC) $2.34 134.88%
    Vaalco Energy Inc. (NYSE: EGY) $2.15 109.06%
    Heat Biologics Inc. (Nasdaq: HTBX) $2.35 99.12%
    ArQule Inc. (Nasdaq: ARQL) $4.88 90.74%
    LiqTech International Inc. (NYSE: LIQT) $0.66 85.60%
    Transenterix Inc. (NYSE: TRXC) $3.46 77.84%

    While last month’s gains are tremendous, they also illustrate the inherent dangers that come with investing in penny stocks.

  • [By Maxx Chatsko]

    Shares of development-stage biopharma ArQule (NASDAQ:ARQL) rose nearly 17% today after the company announced two appointments to its management team in two newly created positions. Dr. Marc Schegerin will serve as senior vice president, corporate strategy, communication, and finance. Dr. Shirish Hirani will serve as senior vice president, program management and product planning. 

Top 10 Biotech Stocks To Own Right Now

One blank check company, Capitol Investment Corp. IV, is on the IPO calendar for the week ahead to raise $350 million. The slowdown in IPO activity marks the start of the annual August lull. Aside from the one SPAC, there will likely be no IPOs for the next four weeks.

Quiet periods for four recent IPOs are set to expire next week. Street research is expected on Monday for gene-edited crop developer Calyxt (CLXT; +48% from IPO), nanoparticle biotech Kala Pharmaceuticals (KALA; +31%) and mortgage REIT TPG RE Finance Trust (TRTX; -1%). Street research for pet meds distributor PetIQ (PETQ; +39%) should arrive on Tuesday.

US IPO Calendar

Issuer
Business

Symbol
Exchange

Deal Size($m)
Market Cap($m)

Price Range
Shares Filed

Pricing
Week

Bookrunners

Top 10 Biotech Stocks To Own Right Now: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Jim Crumly]

    As for individual stocks, shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) fell despite the announcement of its first-ever drug approval, and those of Sysco (NYSE:SYY) rose on earnings.

  • [By Jim Crumly]

    You would think that when a drug company that’s been working for 16 years to develop drugs using a novel therapeutic approach wins its first-ever approval from the U.S. Food and Drug Administration (FDA), confetti would fall from the ceiling and its investors would be celebrating a huge stock gain the next day. That didn’t happen this week for shareholders of Alnylam Pharmaceuticals (NASDAQ:ALNY), with shares dropping 6.6% the day after the announcement, and there were two main reasons for that.

  • [By Cory Renauer]

    Taking a medical breakthrough from concept through commercial success is like ascending a mountain that grows taller and more treacherous with every setback. It’s taken Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) 16 years to launch its first drug, so challenges have had plenty of time to take up positions along this company’s path to a successful first launch.

  • [By Brian Orelli]

    The delay in an FDA decision for Tegsedi puts it behind competitor Alnylam Pharmaceuticals (NASDAQ:ALNY), which expects to hear from the FDA by Aug. 11 for its hATTR drug patisiran. But Sarah Boyce, the president at Akcea Therapeutics, doesn’t think a few months will really matter: “We don’t really feel that’s going to have any impact and the drugs will be close enough together from a launch perspective. So not really [going] to make any adjustments, and we’re very well prepared to be ready to launch following approval.”

  • [By Ethan Ryder]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by stock analysts at ValuEngine from a “buy” rating to a “hold” rating in a report released on Tuesday.

  • [By Jim Crumly]

    Drug giant Pfizer released details of a successful trial of a drug for heart damage from a rare disease, and although that company’s stock had little reaction, falling 1.9%, shares of companies with potentially competing drugs reacted sharply. Alnylam Pharmaceuticals (NASDAQ:ALNY) soared 16.2%, Ionis Pharmaceuticals (NASDAQ:IONS) jumped 7.8%, and Eidos Therapeutics (NASDAQ:EIDX) plunged 31.1%.

Top 10 Biotech Stocks To Own Right Now: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By Brian Orelli]

    Likewise, Biogen (NASDAQ:BIIB) and Ionis Pharmaceuticals (NASDAQ:IONS), which have the only SMA drug on the market, are feeling the heat from the promising data with shares down 5.6% and 7.3%, respectively.

  • [By Lisa Levin] Companies Reporting Before The Bell
    United Technologies Corporation (NYSE: UTX) is estimated to report quarterly earnings at $1.51 per share on revenue of $14.62 billion.
    The Coca-Cola Company (NYSE: KO) is expected to report quarterly earnings at $0.46 per share on revenue of $7.31 billion.
    Caterpillar Inc. (NYSE: CAT) is projected to report quarterly earnings at $2.07 per share on revenue of $11.93 billion.
    Verizon Communications Inc. (NYSE: VZ) is expected to report quarterly earnings at $1.11 per share on revenue of $31.22 billion.
    Lockheed Martin Corporation (NYSE: LMT) is estimated to report quarterly earnings at $3.42 per share on revenue of $11.28 billion.
    The Sherwin-Williams Company (NYSE: SHW) is projected to report quarterly earnings at $3.15 per share on revenue of $3.94 billion.
    Biogen Inc. (NASDAQ: BIIB) is expected to report quarterly earnings at $5.92 per share on revenue of $3.15 billion.
    3M Company (NYSE: MMM) is estimated to report quarterly earnings at $2.52 per share on revenue of $8.26 billion.
    JetBlue Airways Corporation (NASDAQ: JBLU) is projected to report quarterly earnings at $0.2 per share on revenue of $1.75 billion.
    Eli Lilly and Company (NYSE: LLY) is expected to report quarterly earnings at $1.13 per share on revenue of $5.49 billion.
    Harley-Davidson, Inc. (NYSE: HOG) is estimated to report quarterly earnings at $0.88 per share on revenue of $1.25 billion.
    Corning Incorporated (NYSE: GLW) is expected to report quarterly earnings at $0.3 per share on revenue of $2.50 billion.
    Centene Corporation (NYSE: CNC) is projected to report quarterly earnings at $1.88 per share on revenue of $13.28 billion.
    The Travelers Companies, Inc. (NYSE: TRV) is estimated to report quarterly earnings at $2.77 per share on revenue of $6.75 billion.
    Wipro Limited (NYSE: WIT) is expected to report quarterly earnings at $0.07 per share on revenue of $2.16 billion.
    PACCAR Inc (NASDAQ: PCAR) is projected to
  • [By Chris Lange]

    Short interest in Biogen Inc. (NASDAQ: BIIB) decreased slightly to 3.09 million shares from the previous 3.15 million. The stock recently traded at $344.57, within a 52-week range of $249.17 to $388.67.

Top 10 Biotech Stocks To Own Right Now: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Foot Locker, Inc. (NYSE: FL) rose 15.3 percent to $53.50 in pre-market trading after the company reported better-than-expected results for its first quarter.
    Evofem Biosciences, Inc. (NASDAQ: EVFM) rose 10.4 percent to $4.58 in pre-market trading. Evofem Biosciences reported closing of public offering of common stock and warrants.
    Resonant Inc. (NASDAQ: RESN) rose 7.3 percent to $4.88 in pre-market trading after declining 1.94 percent on Thursday.
    SolarEdge Technologies, Inc. (NASDAQ: SEDG) shares rose 5.7 percent to $59.65 in pre-market trading after falling 8.43 percent on Thursday.
    Yirendai Ltd. (NYSE: YRD) rose 5 percent to $30.00 in pre-market trading after reporting Q1 results.
    Deckers Outdoor Corp (NYSE: DECK) rose 4.9 percent to $108.75 in pre-market trading after reporteingd better-than-expected results for its fiscal fourth quarter.
    Blue Apron Holdings, Inc. (NYSE: APRN) rose 4.2 percent to $3.21 in pre-market trading after gaining 3.70 percent on Thursday.
    Recro Pharma, Inc. (NASDAQ: REPH) rose 4 percent to $5.85 in pre-market trading after dropping 54.67 percent on Thursday.
    ArQule, Inc. (NASDAQ: ARQL) rose 3.8 percent to $4.70 in pre-market trading after gaining 4.86 percent on Thursday.
    Babcock & Wilcox Enterprises, Inc. (NYSE: BW) shares rose 2.9 percent to $2.85 in pre-market trading after climbing 7.78 percent on Thursday.
    Bilibili Inc. (NASDAQ: BILI) shares rose 2.5 percent to $14.20 in pre-market trading after surging 11.33 percent on Thursday.

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

  • [By Joseph Griffin]

    ArQule (NASDAQ:ARQL)‘s stock had its “buy” rating restated by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports. They currently have a $6.00 price target on the biotechnology company’s stock, up from their prior price target of $5.00. Needham & Company LLC’s price target suggests a potential upside of 134.38% from the company’s previous close.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on ArQule (ARQL)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Maxx Chatsko]

    Shares of development-stage biopharma ArQule (NASDAQ:ARQL) rose nearly 17% today after the company announced two appointments to its management team in two newly created positions. Dr. Marc Schegerin will serve as senior vice president, corporate strategy, communication, and finance. Dr. Shirish Hirani will serve as senior vice president, program management and product planning. 

  • [By Joseph Griffin]

    Shares of ArQule, Inc. (NASDAQ:ARQL) were down 5.4% during trading on Wednesday . The company traded as low as $4.71 and last traded at $4.73. Approximately 3,358,864 shares traded hands during trading, an increase of 289% from the average daily volume of 863,008 shares. The stock had previously closed at $5.00.

  • [By Joseph Griffin]

    ValuEngine upgraded shares of ArQule (NASDAQ:ARQL) from a buy rating to a strong-buy rating in a research report released on Tuesday.

    Several other equities analysts have also issued reports on ARQL. Zacks Investment Research upgraded ArQule from a hold rating to a buy rating and set a $2.50 price objective for the company in a research report on Tuesday, March 20th. BidaskClub upgraded ArQule from a buy rating to a strong-buy rating in a research report on Saturday, March 24th. B. Riley set a $4.00 price objective on ArQule and gave the company a buy rating in a research report on Monday, March 26th. Leerink Swann upgraded ArQule from a market perform rating to an outperform rating in a research report on Thursday, April 5th. Finally, Roth Capital boosted their price objective on ArQule from $5.00 to $6.00 and gave the company a buy rating in a research report on Tuesday, April 17th. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and two have issued a strong buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $5.35.

Top 10 Biotech Stocks To Own Right Now: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Todd Campbell]

    Neulasta has been one of Amgen’s (NASDAQ:AMGN) crown jewels for years, but following FDA approval of Mylan’s (NASDAQ:MYL) Neulasta biosimilar this week, Amgen could see Neulasta’s revenue slow to a trickle. Is Mylan about to deliver a big blow to Amgen’s market share? Read on to find out what’s at stake for these companies and their investors.

  • [By Dan Caplinger]

    The iShares biotech ETF has a structure that’s familiar to anyone who invests regularly in exchange-traded funds. The ETF tracks an index of nearly 200 biotech and pharmaceutical stocks, with roughly 80% of assets dedicated to true biotechs and the rest split evenly between pharma and life sciences equipment and services providers. Top ETF holdings Biogen (NASDAQ:BIIB), Amgen (NASDAQ:AMGN), and Gilead Sciences (NASDAQ:GILD) make up a total of roughly 25% of the fund’s assets.

  • [By Chris Lange]

    Amgen Inc. (NASDAQ: AMGN) saw its short interest fall to 9.79 million shares from the previous level of 10.46 million. Shares were last seen at $170.00, in a 52-week trading range of $152.16 to $201.23.

  • [By ]

    Amgen (Nasdaq: AMGN) — Amgen is a leading global biotech developer with a diverse product portfolio and promising development pipeline. The company has special expertise in cancer research and renal failure (kidney disease) treatments. Its biggest blockbuster is the anti-inflammatory drug Enbrel, used primarily for rheumatoid arthritis, which is in the top-five worldwide with annual sales of nearly $8 billion.

Top 10 Biotech Stocks To Own For 2019

Biotechnology stocks can pop or drop because of clinical trial successes or failures, and that makes investing in biotech stocks riskier than investing in other industries. Nevertheless, the rewards for those biotech companies that successfully innovate new therapies can be significant, and that makes stocks like Regenxbio (NASDAQ:RGNX), Regeneron Pharmaceuticals (NASDAQ:REGN), and AbbVie (NYSE:ABBV) worth considering. Read on to learn more about these companies and why some of our Motley Fools think they could be top stocks to add to portfolios this month.

This gene therapy stock could be onto something big

Todd Campbell (Regenxbio): If you’re willing to take on some risk in your growth portfolio, then you might want to consider Regenxbio, a clinical-stage biotech working on a novel approach that could make gene therapy safer and more effective.

IMAGE SOURCE: GETTY IMAGES.

Top 10 Biotech Stocks To Own For 2019: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Keith Speights]

    Speaking of competition, Ionis should have its hands full battling rivals for Tegsedi assuming the drug wins approval. Alnylam (NASDAQ:ALNY) anticipates winning FDA approval for its hATTR drug patisiran within a few weeks. Because the FDA delayed its decision on Tegsedi, Alnylam appears to be in position to reach the market first. In addition to its first-mover advantage, patisiran appears to have an edge over Tegsedi in efficacy and safety based on clinical data for the two drugs. 

  • [By Shane Hupp]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lowered by equities research analysts at Morgan Stanley from $107.00 to $99.00 in a report released on Friday. The firm presently has an “equal weight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s price objective would indicate a potential upside of 3.97% from the stock’s current price.

  • [By Brian Orelli]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) released first-quarter results last week, but all eyes were looking forward as the company waits for a potential approval of its hereditary TTR amyloidosis (ATTR) drug, patisiran.

  • [By Joseph Griffin]

    Northern Trust Corp lifted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 4.4% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 492,768 shares of the biopharmaceutical company’s stock after purchasing an additional 20,992 shares during the period. Northern Trust Corp owned about 0.49% of Alnylam Pharmaceuticals worth $48,533,000 at the end of the most recent quarter.

Top 10 Biotech Stocks To Own For 2019: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Shares of ArQule, Inc. (NASDAQ:ARQL) were down 5.4% during trading on Wednesday . The company traded as low as $4.71 and last traded at $4.73. Approximately 3,358,864 shares traded hands during trading, an increase of 289% from the average daily volume of 863,008 shares. The stock had previously closed at $5.00.

  • [By Lisa Levin] Gainers
    Melinta Therapeutics, Inc. (NASDAQ: MLNT) shares surged 20.6 percent to $6.39. WBB Securities upgraded Melinta Therapeutics from Hold to Speculative Buy.
    Shoe Carnival, Inc. (NASDAQ: SCVL) shares climbed 17.2 percent to $30.87 after the company reported upbeat quarterly earnings.
    Acorn International, Inc. (NYSE: ATV) shares rose 15.2 percent to $28.804 after the company declared a special one-time cash dividend of $14.97 per ADS.
    Foot Locker, Inc. (NYSE: FL) gained 15 percent to $53.35 after the company reported better-than-expected results for its first quarter.
    Sears Hometown and Outlet Stores, Inc. (NASDAQ: SHOS) surged 14.2 percent to $2.625.
    ArQule, Inc. (NASDAQ: ARQL) rose 13 percent to $5.12 after gaining 4.86 percent on Thursday.
    Quality Systems, Inc. (NASDAQ: QSII) gained 12.8 percent to $16.97 after the company posted better-than-expected FQ4 results.
    Loma Negra Compañía Industrial Argentina Sociedad Anónima (NYSE: LOMA) shares rose 12 percent to $12.94.
    ArQule, Inc. (NASDAQ: ARQL) shares rose 12 percent to $5.07.
    Mirati Therapeutics, Inc. (NASDAQ: MRTX) climbed 11.4 percent to $43.50.
    Zai Lab Limited (NASDAQ: ZLAB) gained 11.3 percent to $24.7000.
    Zymeworks Inc. (NASDAQ: ZYME) rose 9.7 percent to $19.64.
    Park City Group, Inc. (NASDAQ: PCYG) climbed 9 percent to $7.90.
    Roku, Inc. (NASDAQ: ROKU) gained 7.9 percent to $38.82 after Citron reversed previously bearish position on the stock.
    Sears Holdings Corporation (NASDAQ: SHLD) shares jumped 7.3 percent to $3.55.
    Deckers Outdoor Corp (NYSE: DECK) rose 3.5 percent to $107.27 after reporting better-than-expected results for its fiscal fourth quarter.

    Check out these big penny stock gainers and losers

  • [By Logan Wallace]

    ValuEngine downgraded shares of ArQule (NASDAQ:ARQL) from a strong-buy rating to a buy rating in a research report sent to investors on Saturday.

    Several other brokerages also recently issued reports on ARQL. Zacks Investment Research upgraded shares of ArQule from a hold rating to a buy rating and set a $2.75 target price for the company in a research note on Tuesday, May 8th. B. Riley set a $4.00 target price on shares of ArQule and gave the company a buy rating in a research note on Monday, March 26th. Roth Capital raised their target price on shares of ArQule from $5.00 to $6.00 and gave the company a buy rating in a research note on Tuesday, April 17th. BidaskClub upgraded shares of ArQule from a hold rating to a buy rating in a research note on Saturday, May 19th. Finally, Leerink Swann upgraded shares of ArQule from a market perform rating to an outperform rating in a research note on Thursday, April 5th. One research analyst has rated the stock with a sell rating, six have issued a buy rating and one has issued a strong buy rating to the company. The company has an average rating of Buy and a consensus price target of $5.35.

  • [By Joseph Griffin]

    ArQule (NASDAQ:ARQL)‘s stock had its “buy” rating restated by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports. They currently have a $6.00 price target on the biotechnology company’s stock, up from their prior price target of $5.00. Needham & Company LLC’s price target suggests a potential upside of 134.38% from the company’s previous close.

  • [By Lisa Levin] Gainers
    Foot Locker, Inc. (NYSE: FL) rose 15.3 percent to $53.50 in pre-market trading after the company reported better-than-expected results for its first quarter.
    Evofem Biosciences, Inc. (NASDAQ: EVFM) rose 10.4 percent to $4.58 in pre-market trading. Evofem Biosciences reported closing of public offering of common stock and warrants.
    Resonant Inc. (NASDAQ: RESN) rose 7.3 percent to $4.88 in pre-market trading after declining 1.94 percent on Thursday.
    SolarEdge Technologies, Inc. (NASDAQ: SEDG) shares rose 5.7 percent to $59.65 in pre-market trading after falling 8.43 percent on Thursday.
    Yirendai Ltd. (NYSE: YRD) rose 5 percent to $30.00 in pre-market trading after reporting Q1 results.
    Deckers Outdoor Corp (NYSE: DECK) rose 4.9 percent to $108.75 in pre-market trading after reporteingd better-than-expected results for its fiscal fourth quarter.
    Blue Apron Holdings, Inc. (NYSE: APRN) rose 4.2 percent to $3.21 in pre-market trading after gaining 3.70 percent on Thursday.
    Recro Pharma, Inc. (NASDAQ: REPH) rose 4 percent to $5.85 in pre-market trading after dropping 54.67 percent on Thursday.
    ArQule, Inc. (NASDAQ: ARQL) rose 3.8 percent to $4.70 in pre-market trading after gaining 4.86 percent on Thursday.
    Babcock & Wilcox Enterprises, Inc. (NYSE: BW) shares rose 2.9 percent to $2.85 in pre-market trading after climbing 7.78 percent on Thursday.
    Bilibili Inc. (NASDAQ: BILI) shares rose 2.5 percent to $14.20 in pre-market trading after surging 11.33 percent on Thursday.

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

  • [By Ethan Ryder]

    ArQule, Inc. (NASDAQ:ARQL) insider Value Fund L. P. Biotechnology sold 1,035,939 shares of the business’s stock in a transaction dated Wednesday, May 30th. The shares were sold at an average price of $5.00, for a total value of $5,179,695.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Top 10 Biotech Stocks To Own For 2019: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By Benzinga News Desk]

    A distillery in a small Spanish town has claimed it invented the original Coca-Cola (NYSE: KO) recipe and now wants recognition: Link

    ECONOMIC DATA
    Initial Jobless Claims For Week Ended May 25 221K vs 225K Economist Estimate, Down From 234K In Prior Week
    Personal Income Apr. Up 0.3%, Personal Spending Up 0.6%
    The Chicago PMI for May is schedule for release at 9:45 a.m. ET.
    The pending home sales index for April will be released at 10:00 a.m. ET.
    The Energy Information Administration’s weekly report on natural gas stocks in underground storage is schedule for release at 10:30 a.m. ET.
    The Energy Information Administration’s weekly report on petroleum inventories will be released at 11:00 a.m. ET.
    Federal Reserve Bank of Atlanta President Raphael Bostic is set to speak at 12:30 p.m. ET.
    Fed Governor Lael Brainard will speak at 1:00 p.m. ET.
    Data on money supply for the recent week will be released at 4:30 p.m. ET.
    Federal Reserve Bank of Dallas President Robert Kaplan is set to speak at 8:30 p.m. ET.
    ANALYST RATINGS
    Canaccord upgrades Biogen (NASDAQ: BIIB) from Hold to Buy
    Morgan Stanley upgrades Corning (NYSE: GLW) from Equal-Weight to Overweight
    Morgan Stanley downgrades Micron (NASDAQ: MU) from Overweight to Equal-Weight
    Cantor downgrades HealthEquity (NASDAQ: HQY) from Overweight to Neutral

    This is a tool used by the Benzinga News Desk each trading day — it's a look at everything happening in the market, in five minutes. To get the full version of this note every morning, click here.

  • [By Keith Speights]

    Three biotech stocks that achieved this feat this week are Nightstar Therapeutics (NASDAQ:NITE), Arbutus Biopharma (NASDAQ:ABUS), and Biogen (NASDAQ:BIIB). What caused these stocks to soar, and are they smart picks to buy now? Here’s what you need to know.

  • [By George Budwell]

    Not surprisingly, biotech titans Celgene (NASDAQ:CELG) and Biogen (NASDAQ:BIIB) are among the leaders in this ongoing biopharma revolution. So, with that theme in mind, let’s attempt to gauge which of these top biotechs is the more attractive long-term buy for investors right now.

Top 10 Biotech Stocks To Own For 2019: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Keith Speights]

    That difficulty hasn’t stopped market research firm EvaluatePharma from trying, though. EvaluatePharma recently published a list of the drugmakers with the projected highest value creation from pipeline products between 2018 and 2024. Here’s why Novartis (NYSE:NVS), AbbVie (NYSE:ABBV), Celgene (NASDAQ:CELG), AstraZeneca (NYSE:AZN), and Amgen (NASDAQ:AMGN) ranked at the top.

  • [By Keith Speights]

    It’s a big drugmaker with a blockbuster immunology drug as its top-selling product. It pays an attractive dividend. And it faces some uncertainties. This description fits Amgen (NASDAQ:AMGN), but it applies just as well to Johnson & Johnson (NYSE:JNJ).

  • [By Chris Lange]

    Amgen Inc. (NASDAQ: AMGN) saw its short interest rise to 10.46 million shares from the previous level of 9.49 million. Shares were last seen at $171.94, in a 52-week trading range of $152.16 to $201.23.

  • [By Keith Speights]

    Amgen (NASDAQ:AMGN) and Gilead Sciences (NASDAQ:GILD) rank among the elite in the world of biotech. Both companies have long track records of success. Both generate huge cash flow, but both also face headwinds.